《大行報告》大和上調新秀麗(01910.HK)目標價至36元 評級「買入」
大和發表研究報告指,新秀麗(01910.HK)管理層今年第二次提高全年經調整後EBITDA利潤率指引,現為19%,較年初累升2個百分點。該行相信集團應該成為每個投資組合的一部分,特別是在大盤疲弱的情況下。
該行指,集團的所有品牌、地區表現理想,而且經調整EBITDA利潤率持續勝於預期,料第四季將達到20%。另外,公司亦重申有意於2024年恢復現金股息。該行上調公司2023至25年的核心每股盈測3至12%,重申「買入」評級,目標價由34元上調至36元。該行相信,目前集團是其覆蓋消費板塊中一隻最被低估的股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.